Oncology
Measuring Biomarkers at Every Stage of Tumor Development
The ability to detect oncology biomarkers at ultra-low levels has the potential to enable new options for diagnostics and treatment in cancer research.
Simoa® assays have the potential to be used to monitor cancer risk, identify early-stage cancers and discriminate between benign and malignant cells. Simoa biomarkers also have the potential to be used prognostically to predict disease outcome, predict progression-free survival and monitor reoccurrence, and to be used to monitor sensitivity to therapy and to aid in treatment decisions.
Click through the alphabet to see available assays
Simoa® In Action:
Decreased concentrations of intracellular signaling proteins in colon cancer patients with BRAF mutations.
Olsen et al. Simoa assays were developed to measure AKT, ERK, and cyclin d concentrations in colon cancer patients. Researchers demonstrated an association between levels of these signaling proteins and mutational BRAF status.
Simoa® In Action:
Enrichment of circulating tumor-derived extracellular vesicles from human plasma
Yoh et al. Researchers developed and validated an enrichment method for tumor-derived extracellular vesicles (EVs) in the blood of lung and breast cancer patients using Simoa, providing new insights into enrichment of specific EV subtypes for liquid biopsy.
